Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | WNT1 | P04628 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | BCR | P11274 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240736 | 1.00 | NUDT1 (0.49) | NUDT1DYRK1ACLK2CLK3CCNK | |
| SCHEMBL31240633 | 0.90 | CCNK (0.54) | NUDT1DYRK1ACLK2CLK3CCNK | |
| SCHEMBL26686484 | 0.90 | CCNK (0.54) | NUDT1DYRK1ACLK2CLK3CCNK | |
| SCHEMBL26685806 | 0.89 | NUDT1 (0.48) | NUDT1DYRK1ACLK2CLK3CCNK | |
| SCHEMBL26686576 | 0.89 | CCNK (0.55) | NUDT1DYRK1ACCNKCDK12CHUK | |
| SCHEMBL30633338 | 0.89 | NUDT1 (0.48) | NUDT1DYRK1ACLK2CLK3CCNK | |
| SCHEMBL30633128 | 0.89 | CCNK (0.55) | NUDT1DYRK1ACCNKCDK12CHUK | |
| SCHEMBL26686625 | 0.89 | MAPK1 (0.52) | NUDT1DYRK1ACLK2CLK3JAK2 | |
| SCHEMBL31240472 | 0.89 | MAPK1 (0.52) | NUDT1DYRK1ACLK2CLK3JAK2 | |
| SCHEMBL30633157 | 0.88 | CHUK (0.56) | NUDT1DYRK1ACCNKCDK12CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | NUDT1 3400/4885DYRK1A 707/4885CLK2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.